Furthermore, knowledge of HER2 status is essential to assess eligibility to HER2-targeted therapy such as with trastuzumab (a humanized monoclonal antibody against the extracellular portion of the HER2 protein, used to treat breast cancer and stomach cancer), which is known to increase overall survival [2]. Here, ERBB2 is linked to breast carcinoma.